Cancer Research UK Clinical Trials Unit at the University of Birmingham started a Phase I trial for leukaemia. Credit: Cancer Research UK.

Cancer Research UK and Experimental Cancer Medicine Centres (ECMC) Network joint venture (JV) Combinations Alliance has started the SeluDex trial, a Phase I clinical study to evaluate selumetinib in combination with dexamethasone for treating leukaemia.

Conducted by the Cancer Research UK Clinical Trials Unit at the University of Birmingham, the trial will initially enrol 42 patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial aims to evaluate both adults and children who have had a relapse of their acute lymphoblastic leukaemia (ALL) or refractory ALL, and who have a mutation in a gene involved in the RAS pathway.

Researchers will investigate the most suitable dose of selumetinib and dexamethasone combination.

They will also collect a number of preliminary information on the effectiveness of the combined treatment.

“If this combination is successful, it could give us an urgently needed new way to treat patients who have relapsed and have few treatment options left.”

The trial is expected to be conducted in 23 centres across the UK and in 11 additional locations spanning six European countries.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SeluDex trial international clinical lead Josef Vormoor said: “Although there are effective treatments for leukaemia, for some patients, the disease can return after they have been treated.

“If this combination is successful, it could give us an urgently needed new way to treat patients who have relapsed and have few treatment options left.”

Selumetinib is an oral, potent and highly selective MEK 1/2 inhibitor developed jointly by AstraZeneca and MSD.

Dexamethasone belongs to a group of drugs called glucocorticoids and is already used for several conditions that include leukaemia.

The treatment can simulate the death of cancer cells.